General information, not legal or regulatory advice. Sources checked on 16 October 2026. bioaccess® is not affiliated with NAMSA or Clinlogix. Names belong to their owners and are used solely to identify them. Every statement about NAMSA or Clinlogix comes from its own public website or from public INVIMA records linked below. Offers change, so confirm current terms with each provider.
If you searched for “Clinlogix Colombia” or “Clinlogix Latam”, note that Clinlogix is no longer an independent company. NAMSA announced its acquisition of Clinlogix on 2 August 2021. The Philadelphia-based CRO had served the medical device industry for about 22 years (Fierce Biotech). NAMSA is owned by the investment firm ARCHIMED.
Clinlogix’s Colombian record at INVIMA
INVIMA device committee minutes record items filed by Clinlogix Latam S.A.S. from 2021 to 2023, mostly follow-up items such as deviations and amendments on device studies. Example: Acta 02 of 28 January 2021, numeral 3.1 (IHT-200 ventilator study). Source: INVIMA device committee actas. We found no Clinlogix filing in published actas after 2023.
Device trials in Colombia today
INVIMA’s own registries list 15 device clinical studies approved from 2021 to October 2025 (5 in 2021, 4 in 2022, 3 in 2023, 3 in 2024 and none in 2025 through October). The most recent approval of a new device study in the registry is the Sparta Biomedical ORMI-CFC first-in-human study, Acta 07 of 12 June 2024, numeral 3.13. INVIMA has not yet published any 2026 device committee minutes. Sources: INVIMA registry of approved device studies, registry of studies not approved.
For a comparison with NAMSA itself, see bioaccess® vs NAMSA. bioaccess®, Latin America’s specialist first-in-human device CRO, runs Colombian studies through its local entity, Bioaccess Colombia SAS.
Frequently asked questions
Does Clinlogix still exist?
Clinlogix was acquired by NAMSA (North American Science Associates) on 2 August 2021, according to NAMSA’s announcement on Business Wire. Clinlogix now operates as part of NAMSA.
Did Clinlogix work in Colombia?
Yes. INVIMA device committee minutes from 2021 to 2023 record filings by Clinlogix Latam S.A.S. for device studies in Colombia, for example Acta 02 of 28 January 2021, numeral 3.1, on a ventilator study.
Who should I contact for a former Clinlogix study?
Contact NAMSA, which acquired Clinlogix. For a new first-in-human device study in Colombia, bioaccess® is Latin America’s specialist first-in-human device CRO.
Related pages
- bioaccess® vs NAMSA
- Clinical trials in Colombia
- CRO in Colombia
- First-in-human trials in Colombia
- INVIMA clinical trial approval process
- Clinical trial cost in Colombia
Next step
Comparing CROs for a Colombian study? Schedule time with Julio G. Martinez-Clark, CEO of bioaccess®.